Consejo Superior de Investigaciones Científicas posted this:Overcoming resistance to Beta-lactam antibiotics in Bacterial speciesCSIC and the University of Würzburg have developed a new method to eliminate antibiotic-resistant bacterial infections using classical antibiotics previously discarded due the occurrence of antibiotic resistance. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.CSIC has developed a procedure for the biotechnological production of 11α hydroxylated steroids by generating and subsequent use of recombinant bacteria. These recombinant bacteria allow to perform microbial biotransformation processes that result in 11αhydroxylated steroid compounds from raw materials such as phytosterols and intermediate products efficiently and economically. These compounds have numerous applications in pharmacology. Companies are sought for implementing and commercializing the new technology under patent license agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Compounds for the treatment of optic neuritisCSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat neuropathies that conduct to optic nerve injury, such as optic neuritis. A company dealing with pharmaceutical or nutraceutical compositions for ophtalmic applications is sought for licensing agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Peptide for cancer control linked to IL13RCSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Antibiotics to treat diseases caused by HelicobacterCSIC, the University of Zaragoza, Institute Pasteur, IISA and ARAID have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Potyvirus viral detection kitCSIC and the Universitat Politècnica de València have developed a method for the detection and quantification of all species of the viral genus Potyvirus present in plant samples. The different species of the genus Potyvirus cause losses of up to 90% of production in crops of high economic interest, such as potato, maize or sugar cane. So far, the only way to identify that the crop was being attacked by a virus of the genus Potyvirus was to make specific detections for each species of the genus. With this new system it is possible to determine if in the samples coming from a culture there is presence of one of the 148 known species of the genus Potyvirus or of some unknown variant of these species. Companies in the agro-food sector interested in incorporating this kit for viral detection are being sought. An offer for Patent Licensing
IDIBELL posted this:Drug repurposing for lupus nephritis therapyDrug repurposing for lupus nephritis therapy. Compound X, already approved for human use in other medical indications, administered orally, can be repurposed for lupus nephritis treatment. The principal goal of compound X therapy in lupus nephritis is to normalize renal function or, at least, to prevent the progressive loss of renal function. ✓ Less side effects than the standard of care ✓ Already approved for human in other medical indications (Reprofiling) ✓ Market with 1 approval in last 50 years
Centre Technology Transfer CITTRU posted this:New UV-blocker for sunscreen with high bactericidal activityThe offered material is based on ZnO nanoparticles, modified with biocompatible polymer – chitosan. The material is characterized by high absorption properties of the sun’s ultraviolet (UV) radiation. Also, high antibacterial activity against resistant bacterial strains and the absence of cytotoxic activity against human skin cells of the material were confirmed. Application: cosmetics, sunscreen, skincare, medical applications
Universidad de Alcalá-OTRI posted this:Compounds for the treatment of Leishmania infectionsThe research group Heterobetainas of the University of Alcalá presents the preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML). The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical
Universidad de Alcalá-OTRI posted this:Endothelial microvesicles with microbicidal effect for the preparation of a medicament or for a direct useThe research group "Cell damage associated with senescence" of the University of Alcalá presents the microbicidal capacity of endothelial microvesicles. These vesicles destroy the main pathogens involved in sepsis and even strains derived from them resistant to multiple antibiotics. They have also been shown to be effective against the biofilms that form these microorganisms. The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies interested in the design of new medicines.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrons functionalized with fatty acids: Formation of micelles and uses in biomedicine as antiviral, antibacterial, antiprionic, antimicrobial and drug transporters.The research group of the University of Alcalá in «Dendrimers for biomedical applications» presents the following invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives of these. Its main field of application is in biomedicine, as non-viral transport agents, as drug transporters, to elaborate a drug, as antimicrobial, antiviral or antipyretic agents. In the environmental sector we also find its application as biocides for water treatment. The group seeks to reach license agreements, collaboration or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers with a polyphenolic nucleus and their use as antiviralsThe research group in «Dendrimers for biomedical applications» of the University of Alcalá presents carbosilane dendrimers with a polyphenolic nucleus, its obtaining procedure and its uses as antiviral, antibacterial and antifungal agents. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies from the biotechnology, pharmaceutical and biomedicine sectors in general.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers and their use as antiviralsThe research group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents these highly branched macromolecules synthesized from a polyfunctional nucleus, of carbosilane structure and functionalized in its periphery with anionic groups that give the macromolecule a negative net charge. In addition, the invention relates to the use of the dendrimers as an antimicrobial and the process for obtaining them. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies in the biotechnology, pharmaceutical and biomedicine sectors in general.
Universidad de Alcalá-OTRI posted this:Metal nanoparticles stabilized with carbosilane dendrons for the treatment of infectious diseases and cancer.The research group in “Dendrimers for biomedical applications” of the University of Alcalá, in collaboration with researchers form the Foundation for Biomedical Research of Gregorio Marañón Hospital in Madrid, present the first example of dendronization of metallic nanoparticles with dendritic systems of ionic carbosilane nature. Also the present invention relates to the method of obtaining these nanoparticles and the use of the mentioned compounds for the treatment of infectious diseases or cancer. The researchers seek for collaboration agreements, licensing or commercial agreements with technical assistance, with companies or institutions from the biomedical sector.